Related Experiment Video

Updated: Apr 5, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.7K

Polo-like kinase and its inhibitors: Ready for the match to start?

Neil D Palmisiano1, Margaret T Kasner2

  • 1Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania.

American Journal of Hematology
|August 22, 2015
PubMed

Insights

Targeting Polo-like kinases (Plks), crucial for cell division, shows promise in treating various cancers. Inhibiting Plks impacts both solid tumors and blood cancers, offering new therapeutic strategies.

Area of Science:

  • Cell biology
  • Oncology
  • Pharmacology

Background:

  • Polo-like kinases (Plks) are essential regulators of the cell cycle.
  • Aberrant Plk expression is implicated in the development of numerous human cancers.
  • Plk inhibition represents a potential therapeutic strategy for malignancies.

Purpose of the Study:

  • To review the fundamental science and clinical applications of Plk inhibitors.
  • To discuss the current state of research on Plks in cancer therapy.
  • To explore future directions for Plk-targeted mitotic inhibitors.

Main Methods:

  • Review of preclinical and clinical studies on Polo-like kinases.
  • Analysis of in vitro and in vivo data regarding Plk inhibition in cancer models.
  • Synthesis of current knowledge on Plk biology and therapeutic potential.

Main Results:

  • Targeting Plks demonstrates significant efficacy in preclinical cancer models.
  • Plk inhibition impacts both solid tumors and hematologic malignancies.
  • Evidence supports Plks as a viable target class for novel cancer therapies.

Conclusions:

  • Polo-like kinases are critical targets for anticancer drug development.
  • Targeted inhibition of Plks offers a promising approach for treating diverse cancers.
  • Further research into Plk inhibitors is warranted to optimize clinical outcomes.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.4K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
32
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.8K